Advertisement

Current Cardiology Reports

, 17:110 | Cite as

Risk Stratification for Primary Prevention of Coronary Artery Disease: Roles of C-Reactive Protein and Coronary Artery Calcium

  • Waqas T. Qureshi
  • Jamal S. Rana
  • Joseph Yeboah
  • Usama bin Nasir
  • Mouaz H. Al-Mallah
Lipid Abnormalities and Cardiovascular Prevention (G De Backer, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Lipid Abnormalities and Cardiovascular Prevention

Abstract

Risk stratification of individuals at risk for atherosclerotic cardiovascular disease (ASCVD) plays an important role in primary prevention of cardiovascular disease. In addition to risk scores derived from conventional cardiovascular risk factors, high sensitivity C-reactive protein (hs-CRP) and coronary artery calcium (CAC) have emerged as two of the widely accepted non traditional risk factors for atherosclerotic disease that have shown incremental prognostic value in predicting cardiovascular events. This review systematically assesses the role of hs-CRP and CAC in various studies and demonstrates meta-analyses of the incremental prognostic value of hs-CRP and CAC in identifying patients at risk of future CVD events. Compared with this, CAC showed better incremental prognostic value and might be a better indicator of ASCVD risk in asymptomatic adults.

Keywords

Statin therapy Cholesterol treatment High sensitivity C reactive protein Coronary artery calcium Risk factors Epidemiology Review 

Notes

Compliance with Ethics Guidelines

Conflict of Interest

Waqas Qureshi, Jamal S. Rana, Joseph Yeboah, Usama bin Nasir, and Mouaz H. Al-Mallah declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Members WG, Roger VL, Go AS, et al. Heart Disease and Stroke Statistics—2012 update: a report from the American Heart Association. Circulation. 2012;125:e2–e220.CrossRefGoogle Scholar
  3. 3.••
    Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1–45. These are the 2013 ACC/AHA cholesterol treatment guidelines that provide evidence of using hs-CRP and CAC in asymptomatic individuals for primary prevention of CAD. PubMedCrossRefGoogle Scholar
  4. 4.
    Rose G. Sick individuals and sick populations. Int J Epidemiol. 1985;14:32–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987–1003.PubMedCrossRefGoogle Scholar
  6. 6.
    Cooney MT, Dudina A, Whincup P, et al. Re-evaluating the Rose approach: comparative benefits of the population and high-risk preventive strategies. Eur J Cardiovasc Prev Rehabil. 2009;16:541–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med. 2004;116(Suppl 6A):9S–16S.PubMedCrossRefGoogle Scholar
  8. 8.
    Rohde LE, Arroyo LH, Rifai N, et al. Plasma concentrations of interleukin-6 and abdominal aortic diameter among subjects without aortic dilatation. Arterioscler Thromb Vasc Biol. 1999;19:1695–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Budoff MJ, Young R, Lopez VA, et al. Progression of coronary calcium and incident coronary heart disease events: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2013;61:1231–9.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.••
    Blaha MJ, Silverman MG, Budoff MJ. Is there a role for coronary artery calcium scoring for management of asymptomatic patients at risk for coronary artery disease?: Clinical risk scores are not sufficient to define primary prevention treatment strategies among asymptomatic patients. Circ Cardiovasc Imaging 2014; 7:398–408; discussion 408. This is a discussion about coronary artery calcium, its use as a risk marker and its limitations in clinical practice.Google Scholar
  11. 11.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRefGoogle Scholar
  12. 12.
    Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.•
    Kaptoge S, Di Angelantonio E, Pennells L, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367:1310–20. This is the largest meta-analysis to date that has examined prognostic value of hs-CRP for coronary heart disease.PubMedCrossRefGoogle Scholar
  14. 14.
    Tillett WS, Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med. 1930;52:561–71.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol. 1983;34:141–212.PubMedCrossRefGoogle Scholar
  16. 16.
    Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111:1805–12.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Albert MA, Glynn RJ, Buring J, et al. C-reactive protein levels among women of various ethnic groups living in the United States (from the Women's Health Study). Am J Cardiol. 2004;93:1238–42.PubMedCrossRefGoogle Scholar
  18. 18.
    Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003;107:391–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98:731–3.PubMedCrossRefGoogle Scholar
  20. 20.
    Ridker PM, Cushman M, Stampfer MJ, et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 1998;97:425–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97:2007–11.PubMedCrossRefGoogle Scholar
  22. 22.
    Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836–43.PubMedCrossRefGoogle Scholar
  23. 23.
    Hein TW, Singh U, Vasquez-Vivar J, et al. Human C-reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo. Atherosclerosis. 2009;206:61–8.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Haverkate F, Thompson SG, Pyke SD, et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 1997;349:462–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387–97.PubMedCrossRefGoogle Scholar
  27. 27.
    Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375:132–40.PubMedCrossRefGoogle Scholar
  28. 28.••
    Yeboah J, McClelland RL, Polonsky TS, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA. 2012;308:788–95. This study has examined multiple biomarkers of coronary heart disease and cardiovascular disease in individuals classified as intermediate risk group in asymptomatic individuals. PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Schiele F, Meneveau N, Seronde MF, et al. C-reactive protein improves risk prediction in patients with acute coronary syndromes. Eur Heart J. 2010;31:290–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Ledue TB, Rifai N. Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment. Clin Chem. 2003;49:1258–71.PubMedCrossRefGoogle Scholar
  31. 31.
    Pencina MJ, D'Agostino Sr RB, D'Agostino Jr RB, et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157–72. discussion 207–112.PubMedCrossRefGoogle Scholar
  32. 32.
    Yousuf O, Mohanty BD, Martin SS, et al. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? J Am Coll Cardiol. 2013;62:397–408.PubMedCrossRefGoogle Scholar
  33. 33.
    Paynter NP, Everett BM, Cook NR. Cardiovascular disease risk prediction in women: is there a role for novel biomarkers? Clin Chem. 2014;60:88–97.PubMedCrossRefGoogle Scholar
  34. 34.
    Folsom AR. Classical and novel biomarkers for cardiovascular risk prediction in the United States. J Epidemiol. 2013;23:158–62.PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
    Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297:611–9.PubMedCrossRefGoogle Scholar
  36. 36.
    DeFilippis AP, Blaha MJ, Ndumele CE, et al. The association of Framingham and Reynolds risk scores with incidence and progression of coronary artery calcification in MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2011;58:2076–83.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.•
    DeFilippis AP, Young R, Carrubba CJ, et al. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med. 2015;162:266–75. This analysis has examined the prognostic value of several traditional and non-traditional risk scores in asymptomatic group of patients. PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Allan GM, Nouri F, Korownyk C, et al. Agreement among cardiovascular disease risk calculators. Circulation. 2013;127:1948–56.PubMedCrossRefGoogle Scholar
  39. 39.
    Siontis GC, Tzoulaki I, Siontis KC, et al. Comparisons of established risk prediction models for cardiovascular disease: systematic review. BMJ. 2012;344:e3318.PubMedCrossRefGoogle Scholar
  40. 40.
    Bazo-Alvarez JC, Quispe R, Peralta F, et al. Agreement between cardiovascular disease risk scores in resource-limited settings: evidence from 5 Peruvian sites. Crit Pathw Cardiol. 2015;14:74–80.PubMedCrossRefGoogle Scholar
  41. 41.
    Wilson PW. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: application to clinical and public health practice: ability of inflammatory markers to predict disease in asymptomatic patients: a background paper. Circulation. 2004;110:e568–571.PubMedCrossRefGoogle Scholar
  42. 42.
    Shivpuri S, Gallo LC, Crouse JR, et al. The association between chronic stress type and C-reactive protein in the multi-ethnic study of atherosclerosis: does gender make a difference? J Behav Med. 2012;35:74–85.PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Bower JK, Lazo M, Juraschek SP, et al. Within-Person Variability in High-Sensitivity C-Reactive Protein. Arch Intern Med. 2012;172:1519–21.Google Scholar
  44. 44.
    Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.PubMedCrossRefGoogle Scholar
  45. 45.
    Elliott P, Chambers JC, Zhang W, et al. Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA. 2009;302:37–48.PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    Savarese G, Rosano GM, Parente A, et al. Reduction of C-reactive protein is not associated with reduced cardiovascular risk and mortality in patients treated with statins. A meta-analysis of 22 randomized trials. Int J Cardiol. 2014;177:152–60.PubMedCrossRefGoogle Scholar
  47. 47.••
    Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769–818. This is the European guideline document for management of dyslipidaemias with evidence behind the guidelines.PubMedCrossRefGoogle Scholar
  48. 48.
    Hingorani AD, Shah T, Casas JP, et al. C-reactive protein and coronary heart disease: predictive test or therapeutic target? Clin Chem. 2009;55:239–55.PubMedCrossRefGoogle Scholar
  49. 49.
    Stary HC. The sequence of cell and matrix changes in atherosclerotic lesions of coronary arteries in the first forty years of life. Eur Heart J. 1990;11(Suppl E):3–19.PubMedCrossRefGoogle Scholar
  50. 50.
    Schmid K, McSharry WO, Pameijer CH, et al. Chemical and physicochemical studies on the mineral deposits of the human atherosclerotic aorta. Atherosclerosis. 1980;37:199–210.PubMedCrossRefGoogle Scholar
  51. 51.
    Engelse MA, Neele JM, Bronckers AL, et al. Vascular calcification: expression patterns of the osteoblast-specific gene core binding factor α-1 and the protective factor matrix gla protein in human atherogenesis. Cardiovasc Res. 2001;52:281–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Ikeda T, Shirasawa T, Esaki Y, et al. Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta. J Clin Invest. 1993;92:2814–20.PubMedCentralPubMedCrossRefGoogle Scholar
  53. 53.
    Detrano RC, Wong ND, French WJ, et al. Prevalence of fluoroscopic coronary calcific deposits in high-risk asymptomatic persons. Am Heart J. 1994;127:1526–32.PubMedCrossRefGoogle Scholar
  54. 54.
    Agatston AS, Janowitz WR, Hildner FJ, et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15:827–32.PubMedCrossRefGoogle Scholar
  55. 55.
    Rumberger JA, Sheedy 3rd PF, Breen JF, et al. Coronary calcium, as determined by electron beam computed tomography, and coronary disease on arteriogram. Effect of patient's sex on diagnosis. Circulation. 1995;91:1363–7.PubMedCrossRefGoogle Scholar
  56. 56.
    Rumberger JA, Brundage BH, Rader DJ, et al. Electron beam computed tomographic coronary calcium scanning: a review and guidelines for use in asymptomatic persons. Mayo Clin Proc. 1999;74:243–52.PubMedCrossRefGoogle Scholar
  57. 57.
    Kaufmann RB, Sheedy 2nd PF, Maher JE, et al. Quantity of coronary artery calcium detected by electron beam computed tomography in asymptomatic subjects and angiographically studied patients. Mayo Clin Proc. 1995;70:223–32.PubMedCrossRefGoogle Scholar
  58. 58.
    Seven E, Husemoen LL, Sehested TS, et al. Adipocytokines, C-reactive protein, and cardiovascular disease: a population-based prospective study. PLoS One. 2015;10:e0128987.PubMedCentralPubMedCrossRefGoogle Scholar
  59. 59.
    Skoglund PH, Arpegard J, Ostergren J, et al. Amino-terminal pro-B-type natriuretic peptide and high-sensitivity C-reactive protein but not cystatin C predict cardiovascular events in male patients with peripheral artery disease independently of ambulatory pulse pressure. Am J Hypertens. 2014;27:363–71.PubMedCrossRefGoogle Scholar
  60. 60.
    Beatty AL, Schiller NB, Whooley MA. Six-minute walk test as a prognostic tool in stable coronary heart disease: data from the heart and soul study. Arch Intern Med. 2012;172:1096–102.PubMedCentralPubMedCrossRefGoogle Scholar
  61. 61.•
    Ahluwalia N, Blacher J, Szabo de Edelenyi F, et al. Prognostic value of multiple emerging biomarkers in cardiovascular risk prediction in patients with stable cardiovascular disease. Atherosclerosis. 2013;228:478–84. This study has examined multiple biomarkers including coronary artery calcium and hs-CRP in known cardiovascular disease patients.PubMedCrossRefGoogle Scholar
  62. 62.
    Miller GJ, Bauer KA, Barzegar S, et al. The effects of quality and timing of venepuncture on markers of blood coagulation in healthy middle-aged men. Thromb Haemost. 1995;73:82–6.PubMedGoogle Scholar
  63. 63.
    Fowkes FG, Housley E, Cawood EH, et al. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1991;20:384–92.PubMedCrossRefGoogle Scholar
  64. 64.
    Shah T, Casas JP, Cooper JA, et al. Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol. 2009;38:217–31.PubMedCentralPubMedCrossRefGoogle Scholar
  65. 65.
    Wilson PW, Nam BH, Pencina M, et al. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch Intern Med. 2005;165:2473–8.PubMedCrossRefGoogle Scholar
  66. 66.
    Boekholdt SM, Hack CE, Sandhu MS, et al. C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993–2003. Atherosclerosis. 2006;187:415–22.PubMedCrossRefGoogle Scholar
  67. 67.
    Stork S, Feelders RA, van den Beld AW, et al. Prediction of mortality risk in the elderly. Am J Med. 2006;119:519–25.PubMedCrossRefGoogle Scholar
  68. 68.
    May M, Lawlor DA, Brindle P, et al. Cardiovascular disease risk assessment in older women: can we improve on Framingham? British Women's Heart and Health prospective cohort study. Heart. 2006;92:1396–401.PubMedCentralPubMedCrossRefGoogle Scholar
  69. 69.
    Folsom AR, Chambless LE, Ballantyne CM, et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med. 2006;166:1368–73.PubMedCrossRefGoogle Scholar
  70. 70.
    Koenig W, Khuseyinova N, Baumert J, et al. Increased concentrations of C-reactive protein and IL-6 but not IL-18 are independently associated with incident coronary events in middle-aged men and women: results from the MONICA/KORA Augsburg case-cohort study, 1984–2002. Arterioscler Thromb Vasc Biol. 2006;26:2745–51.PubMedCrossRefGoogle Scholar
  71. 71.
    Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med. 2006;145:21–9.PubMedCrossRefGoogle Scholar
  72. 72.
    Sattar N, Murray HM, McConnachie A, et al. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation. 2007;115:981–9.PubMedCrossRefGoogle Scholar
  73. 73.
    Cao JJ, Arnold AM, Manolio TA, et al. Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: the Cardiovascular Health Study. Circulation. 2007;116:32–8.PubMedCrossRefGoogle Scholar
  74. 74.
    Blyme A, Asferg C, Nielsen OW, et al. High sensitivity C reactive protein as a prognostic marker in patients with mild to moderate aortic valve stenosis during lipid-lowering treatment: an SEAS substudy. Open Heart. 2015;2:e000152.PubMedCentralPubMedCrossRefGoogle Scholar
  75. 75.
    Zhao Q, Du JS, Han DM, et al. High-sensitive factor I and C-reactive protein based biomarkers for coronary artery disease. Int J Clin Exp Med. 2014;7:5158–69.PubMedCentralPubMedGoogle Scholar
  76. 76.
    Shaw LJ, Raggi P, Schisterman E, et al. Prognostic value of cardiac risk factors and coronary artery calcium screening for all-cause mortality. Radiology. 2003;228:826–33.PubMedCrossRefGoogle Scholar
  77. 77.
    Greenland P, LaBree L, Azen SP, et al. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA. 2004;291:210–5.PubMedCrossRefGoogle Scholar
  78. 78.
    Budoff MJ, Shaw LJ, Liu ST, et al. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol. 2007;49:1860–70.PubMedCrossRefGoogle Scholar
  79. 79.
    Budoff MJ, Shavelle DM, Lamont DH, et al. Usefulness of electron beam computed tomography scanning for distinguishing ischemic from nonischemic cardiomyopathy. J Am Coll Cardiol. 1998;32:1173–8.PubMedCrossRefGoogle Scholar
  80. 80.
    Budoff MJ, Nasir K, McClelland RL, et al. Coronary calcium predicts events better with absolute calcium scores than age-sex-race/ethnicity percentiles: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2009;53:345–52.PubMedCentralPubMedCrossRefGoogle Scholar
  81. 81.
    Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008;358:1336–45.PubMedCrossRefGoogle Scholar
  82. 82.
    Desai MY, Halliburton S, Masri A, et al. Reclassification of cardiovascular risk with coronary calcium scoring in subjects without documented coronary heart disease: comparison with risk assessment based on Reynolds Risk Score. J Am Coll Cardiol. 2012;59:E1186.CrossRefGoogle Scholar
  83. 83.
    Callister TQ, Cooil B, Raya SP, et al. Coronary artery disease: improved reproducibility of calcium scoring with an electron-beam CT volumetric method. Radiology. 1998;208:807–14.PubMedCrossRefGoogle Scholar
  84. 84.
    Criqui MH, Denenberg JO, Ix JH, et al. Calcium density of coronary artery plaque and risk of incident cardiovascular events. JAMA. 2014;311:271–8.PubMedCentralPubMedCrossRefGoogle Scholar
  85. 85.
    Arad Y, Goodman KJ, Roth M, et al. Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: the St. Francis Heart Study. J Am Coll Cardiol. 2005;46:158–65.PubMedCrossRefGoogle Scholar
  86. 86.••
    Yeboah J, Carr JJ, Terry JG, et al. Computed tomography-derived cardiovascular risk markers, incident cardiovascular events, and all-cause mortality in nondiabetics: the Multi-Ethnic Study of Atherosclerosis. Eur J Prev Cardiol. 2014;21:1233–41. This study provides various traditional and non-traditional biomarkers for cardiovascular disease and all-cause mortality in non-diabetic patients.PubMedCentralPubMedCrossRefGoogle Scholar
  87. 87.
    Polonsky TS, McClelland RL, Jorgensen NW, et al. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA. 2010;303:1610–6.PubMedCentralPubMedCrossRefGoogle Scholar
  88. 88.
    Sarwar A, Shaw LJ, Shapiro MD, et al. Diagnostic and prognostic value of absence of coronary artery calcification. JACC Cardiovasc Imaging. 2009;2:675–88.PubMedCrossRefGoogle Scholar
  89. 89.
    Blaha M, Budoff MJ, Shaw LJ, et al. Absence of coronary artery calcification and all-cause mortality. JACC Cardiovasc Imaging. 2009;2:692–700.PubMedCrossRefGoogle Scholar
  90. 90.
    Budoff MJ, McClelland RL, Nasir K, et al. Cardiovascular events with absent or minimal coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J. 2009;158:554–61.PubMedCentralPubMedCrossRefGoogle Scholar
  91. 91.
    Rijlaarsdam-Hermsen D, Kuijpers D, van Dijkman PR. Diagnostic and prognostic value of absence of coronary artery calcification in patients with stable chest symptoms. Neth Heart J. 2011;19:223–8.PubMedCentralPubMedCrossRefGoogle Scholar
  92. 92.
    Joshi PH, Blaha MJ, Budoff MJ, et al. The ten year prognostic value of zero and minimal coronary artery calcium: the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2014;130:A11701.Google Scholar
  93. 93.
    Al-Mallah MH. Does coronary CT angiography improve risk stratification over coronary artery calcium scoring in symptomatic patients with a low pre-test probability of coronary artery disease and a CAC of zero? Reply. Eur Heart J Cardiovasc Imaging. 2014;15:232–3.PubMedCrossRefGoogle Scholar
  94. 94.
    Cohen R, Budoff M, McClelland RL, et al. Significance of a positive family history for coronary heart disease in patients with a zero coronary artery calcium score (from the Multi-Ethnic Study of Atherosclerosis). Am J Cardiol. 2014;114:1210–4.PubMedCentralPubMedCrossRefGoogle Scholar
  95. 95.
    Pursnani A, Massaro JM, D'Agostino Sr RB, et al. Guideline-based statin eligibility, coronary artery calcification, and cardiovascular events. JAMA. 2015;314:134–41.PubMedCrossRefGoogle Scholar
  96. 96.
    Rozanski A, Gransar H, Shaw LJ, et al. Impact of coronary artery calcium scanning on coronary risk factors and downstream testing the EISNER (Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research) prospective randomized trial. J Am Coll Cardiol. 2011;57:1622–32.PubMedCentralPubMedCrossRefGoogle Scholar
  97. 97.
    Blaha MJ, Budoff MJ, DeFilippis AP, et al. Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study. Lancet. 2011;378:684–92.PubMedCentralPubMedCrossRefGoogle Scholar
  98. 98.
    Blaha MMB, Blankstein R, Budoff M, Sibley C, Gregory B, Szklo M, et al. Comparing zero coronary artery calcium with other negative risk factors for coronary heart disease—Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2011;124:A14321.Google Scholar
  99. 99.
    Hosseinsabet A, Mohebbi A, Almasi A. C-reactive protein and coronary calcium score association in coronary artery disease. Cardiol J. 2008;15:431–6.PubMedGoogle Scholar
  100. 100.
    Redberg RF, Rifai N, Gee L, et al. Lack of association of C-reactive protein and coronary calcium by electron beam computed tomography in postmenopausal women: implications for coronary artery disease screening. J Am Coll Cardiol. 2000;36:39–43.PubMedCrossRefGoogle Scholar
  101. 101.
    Mohlenkamp S, Lehmann N, Moebus S, et al. Quantification of coronary atherosclerosis and inflammation to predict coronary events and all-cause mortality. J Am Coll Cardiol. 2011;57:1455–64.PubMedCrossRefGoogle Scholar
  102. 102.
    Elias-Smale SE, Proenca RV, Koller MT, et al. Coronary calcium score improves classification of coronary heart disease risk in the elderly: the Rotterdam study. J Am Coll Cardiol. 2010;56:1407–14.PubMedCrossRefGoogle Scholar
  103. 103.
    Rana JS, Gransar H, Wong ND, et al. Comparative value of coronary artery calcium and multiple blood biomarkers for prognostication of cardiovascular events. Am J Cardiol. 2012;109:1449–53.PubMedCrossRefGoogle Scholar
  104. 104.••
    Shreibati JB, Baker LC, McConnell MV, et al. Outcomes after coronary artery calcium and other cardiovascular biomarker testing among asymptomatic medicare beneficiaries. Circ Cardiovasc Imaging. 2014;7:655–62. This is the only head to head propensity score matched comparison of coronary artery calcium and hs-CRP in asymptomatic >65 year old adults. PubMedCrossRefGoogle Scholar
  105. 105.
    Arad Y, Spadaro LA, Roth M, et al. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial. J Am Coll Cardiol. 2005;46:166–72.PubMedCrossRefGoogle Scholar
  106. 106.
    Matsuura N, Urashima M, Fukumoto W, et al. Radiation dose reduction at coronary artery calcium scoring by using a low tube current technique and hybrid iterative reconstruction. J Comput Assist Tomogr. 2015;39:119–24.PubMedCrossRefGoogle Scholar
  107. 107.
    Alqarqaz M, Zaidan M, Al-Mallah MH. Prevalence and predictors of atherosclerosis in symptomatic patients with zero calcium score. Acad Radiol. 2011;18:1437–41.PubMedCrossRefGoogle Scholar
  108. 108.
    Villines TC, Hulten EA, Shaw LJ, et al. Prevalence and severity of coronary artery disease and adverse events among symptomatic patients with coronary artery calcification scores of zero undergoing coronary computed tomography angiography: results from the CONFIRM (Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter) registry. J Am Coll Cardiol. 2011;58:2533–40.PubMedCrossRefGoogle Scholar
  109. 109.
    Greenland P, Alpert JS, Beller GA, et al. ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2010;122:2748–64.PubMedCrossRefGoogle Scholar
  110. 110.
    O'Keefe JH, Patil HR, Lavie CJ, et al. Potential adverse cardiovascular effects from excessive endurance exercise. Mayo Clin Proc. 2012;87:587–95.PubMedCentralPubMedCrossRefGoogle Scholar
  111. 111.
    Yeboah J, Polonsky TS, Young R, et al. Utility of Non-Traditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 ACC/AHA Cholesterol Guidelines. Circulation 2015.Google Scholar
  112. 112.
    Vliegenthart R, Oudkerk M, Song B, et al. Coronary calcification detected by electron-beam computed tomography and myocardial infarction. The Rotterdam Coronary Calcification Study. Eur Heart J. 2002;23:1596–603.PubMedCrossRefGoogle Scholar
  113. 113.
    Erbel R, Mohlenkamp S, Moebus S, et al. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study. J Am Coll Cardiol. 2010;56:1397–406.PubMedCrossRefGoogle Scholar
  114. 114.
    Becker A, Leber A, Becker C, et al. Predictive value of coronary calcifications for future cardiac events in asymptomatic individuals. Am Heart J. 2008;155:154–60.PubMedCrossRefGoogle Scholar
  115. 115.••
    Hecht HS. Coronary artery calcium scanning: past, present, and future. JACC Cardiovasc Imaging. 2015;8:579–96. This is a comprehensive review of coronary artery calcium, its use and value in the current era. PubMedCrossRefGoogle Scholar
  116. 116.
    Diederichsen AC, Mahabadi AA, Gerke O, et al. Increased discordance between HeartScore and coronary artery calcification score after introduction of the new ESC prevention guidelines. Atherosclerosis. 2015;239:143–9.PubMedCrossRefGoogle Scholar
  117. 117.
    Al-Mallah MH, Qureshi W, Lin FY, et al. Does coronary CT angiography improve risk stratification over coronary calcium scoring in symptomatic patients with suspected coronary artery disease? Results from the prospective multicenter international CONFIRM registry. Eur Heart J Cardiovasc Imaging. 2014;15:267–74.PubMedCrossRefGoogle Scholar
  118. 118.
    Taylor AJ, Cerqueira M, Hodgson JM, et al. ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 Appropriate Use Criteria for Cardiac Computed Tomography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the Society of Cardiovascular Computed Tomography, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the American Society of Nuclear Cardiology, the North American Society for Cardiovascular Imaging, the Society for Cardiovascular Angiography and Interventions, and the Society for Cardiovascular Magnetic Resonance. Circulation. 2010;122:e525–555.PubMedCrossRefGoogle Scholar
  119. 119.••
    Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33:1635–701. These are the European guidelines for cardiovascular disease prevention in clinical practice that also provide evidence behind use of traditional and non-traditional risk markers of cardiovascular disease. PubMedCrossRefGoogle Scholar
  120. 120.
    Earls JP, Woodard PK, Abbara S, et al. ACR appropriateness criteria asymptomatic patient at risk for coronary artery disease. J Am Coll Radiol. 2014;11:12–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Waqas T. Qureshi
    • 1
  • Jamal S. Rana
    • 2
    • 3
    • 5
  • Joseph Yeboah
    • 1
  • Usama bin Nasir
    • 1
  • Mouaz H. Al-Mallah
    • 4
    • 6
  1. 1.Division of Cardiovascular Medicine, Department of Internal MedicineWake Forest University School of MedicineWinston-SalemUSA
  2. 2.Division of CardiologyKaiser Permanente Northern CaliforniaOaklandUSA
  3. 3.Department of MedicineUniversity of California, San FranciscoSan FranciscoUSA
  4. 4.Cardiac Imaging King Abdul-Aziz Cardiac CenterRiyadhKingdom of Saudi Arabia
  5. 5.Division of ResearchKaiser Permanente Northern CaliforniaOaklandUSA
  6. 6.King Abdullah International Medical research centerRiyadhKingdom of Saudi Arabia

Personalised recommendations